Dynavax Technologies Corporation Logo

Print Print page   Email Email page   PDF Download PDF    Add to Briefcase
« Previous Release | Next Release »



Dynavax Conference Call / Webcast Tomorrow on Topline Phase 3 Data and Q2 Financial Results

BERKELEY, CA -- (MARKET WIRE) -- 07/19/11 -- Dynavax Technologies Corporation (NASDAQ: DVAX) said it will host a conference call and webcast tomorrow, Wednesday, July 20, 2011, to discuss topline Phase 3 data and its second quarter 2011 financial results at 9:00 a.m. Eastern Daylight Time / 6:00 a.m. Pacific Daylight Time.

To join the Conference Call, please dial 1-877-280-7280. International callers can dial 1-707-287-9365. A telephonic replay of the discussion will be available 90 minutes after its conclusion and through August 3, 2011 by dialing 1-855-859-2056, access code: 85190076. International callers can dial 1-404-537-3406, access code: 85190076.

The webcast can be accessed on Dynavax's website at http://investors.dynavax.com/events.cfm. A webcast replay of the discussion will be available on Dynavax's website, 90 minutes after its conclusion and through August 3, 2011.

About HEPLISAV

HEPLISAV™ is an investigational adult hepatitis B vaccine. In an earlier completed pivotal Phase 3 trial, HEPLISAV demonstrated increased, rapid protection with fewer doses than current licensed vaccines. Dynavax has worldwide commercial rights to HEPLISAV and is developing the vaccine for large, high-value populations that are less responsive to current licensed vaccines, including individuals with chronic kidney disease. HEPLISAV combines hepatitis B surface antigen with a proprietary Toll-like Receptor 9 agonist known as ISS to enhance the immune response.

About Dynavax

Dynavax Technologies Corporation, a clinical-stage biopharmaceutical company, discovers and develops novel products to prevent and treat infectious and inflammatory diseases. The Company's lead product candidate is HEPLISAV, a Phase 3 investigational adult hepatitis B vaccine designed to provide rapid and superior protection with fewer doses than current licensed vaccines. For more information visit www.dynavax.com.

Contacts:

Shari Annes

Investor Relations

510-665-7211

Email Contact



Jennifer Lew

Vice President, Finance

510-665-7217

Email Contact



Source: Dynavax Technologies

News Provided by Acquire Media

Close window | Back to top